MLICM
JUNO

Metropolitan Life Insurance Company (MetLife)’s Juno Therapeutics, Inc. JUNO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,978
Closed -$90K – 2531
2017
Q4 		$90K Buy
1,978
+71
+4% +$3.54K ﹤0.01% 2368
2017
Q3 		$86K Buy
1,907
+174
+10% +$5.93K ﹤0.01% 2425
2017
Q2 		$52K Sell
1,733
-2,332
-57% -$57.5K ﹤0.01% 2545
2017
Q1 		$90K Hold
4,065
– – ﹤0.01% 2456
2016
Q4 		$77K Sell
4,065
-179
-4% -$4.38K ﹤0.01% 2561
2016
Q3 		$127K Sell
4,244
-197
-4% -$6.13K ﹤0.01% 2520
2016
Q2 		$171K Buy
4,441
+3,548
+397% +$147K ﹤0.01% 2432
2016
Q1 		$34K Hold
893
– – ﹤0.01% 2483
2015
Q4 		$39K Buy
893
+23
+3% +$1.14K ﹤0.01% 2556
2015
Q3 		$35K Hold
870
– – ﹤0.01% 2644
2015
Q2 		$46K Buy
+870
New +$46.2K ﹤0.01% 2672

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Metropolitan Life Insurance Company (MetLife)'s JUNO Position: Q1 2018 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,978 shares — an estimated $90K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in JUNO in Q2 2015 and held it in 11 quarters. The position peaked at $171K in Q2 2016. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,978 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $90K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 11 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Juno Therapeutics, Inc. position peaked at $171K in Q2 2016.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2018, filed 15 May 2018.